SciBase Launches DETECT-AD Study to Predict Atopic Dermatitis Flares
Event summary
- First patient enrolled in DETECT-AD study on June 10, 2026.
- Study aims to assess SciBase's Electrical Impedance Spectroscopy (EIS) for predicting atopic dermatitis flares.
- Collaboration with Castle Biosciences marks first joint study.
- Multicenter prospective clinical trial seeks to enable proactive interventions for AD patients.
The big picture
SciBase's DETECT-AD study represents a strategic shift toward predictive, personalized care in dermatology, addressing the unmet need for proactive management of atopic dermatitis. The collaboration with Castle Biosciences suggests a push toward broader clinical validation of SciBase's AI-powered diagnostic platform. Success in this study could position the company as a leader in predictive dermatology solutions, potentially expanding its market reach beyond current applications.
What we're watching
- Technology Validation
- Whether SciBase's EIS method can demonstrate reliable flare prediction in atopic dermatitis patients.
- Market Expansion
- How this collaboration with Castle Biosciences positions SciBase in the competitive dermatology diagnostics space.
- Regulatory Pathway
- The pace at which positive study results could translate into regulatory approvals or commercial adoption.
Related topics